The insider sales are routine post-offering liquidity events — no bearish signal. Monitor the upcoming Phase 3 data readout for deucrictibant (expected H2 2026) as the primary catalyst. The $107.5M raise provides runway into H1 2028, reducing near-term financing risk.
Price Chart
Executive Summary
Five Pharvaris insiders, including the CEO and CCO, sold a total of ~$1.08M in open-market sales over a 7-day window, following a $107.5M equity offering that closed 14 days prior. The sales represent ~0.05% of the $2.1B market cap — a trivial amount — and are likely liquidity-driven after the offering's lock-up expiration rather than a bearish signal on the pipeline.
Key Financial Metrics
Key Facts
- Five insiders sold a combined ~36,300 shares for ~$1.08M in open-market transactions (May 13-20, 2026).
- CEO Berndt Modig sold 2,292 shares for ~$67K; CCO Wim Souverijns sold 10,000 shares for ~$299K.
- Total sales equal ~0.05% of Pharvaris' $2.1B market cap — well below the 0.1% materiality threshold.
- The cluster follows a $107.5M underwritten public offering (424B5, May 8, 2026) that extended cash runway into H1 2028.
- Director Elisabeth Bjork also exercised 10,000 options at $8.05/share ($80,500 cost) and sold the shares for $293K — a net cash-out of ~$213K.
- Historical calibration shows cluster sells at this company have no predictive edge (score-6 observedP=29%, avg net alpha -0.96%).
Financial Impact
Total insider sales of ~$1.08M, or 0.05% of market cap — immaterial relative to company size.
Risk Factors
- Phase 3 clinical trial failure for deucrictibant in HAE would be a material negative catalyst.
- Further insider selling at higher volumes (>0.5% of market cap) could signal loss of confidence.
- Cash burn rate may accelerate if US commercialization costs ramp faster than expected.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PHVS-1779476076663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access